Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 0.79 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.74 |
| ▸ | IDO1 | P14902 | 2/20 | 0.74 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.65 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.65 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626656 | 0.92 | ACHE (0.80) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL17626653 | 0.92 | ACHE (0.80) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL22465613 | 0.88 | CACNA1H (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL145714 | 0.87 | CACNA1H (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL29394512 | 0.87 | CACNA1H (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL145713 | 0.87 | CACNA1H (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL22465745 | 0.87 | CACNA1H (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL17626616 | 0.85 | IDO1 (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL564110 | 0.85 | IDO1 (1.00) | CACNA1HCACNA1GESR1MAPTMAPK1 | |
| SCHEMBL22465767 | 0.85 | CACNA1H (0.79) | CACNA1HCACNA1GESR1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000465-B1 | T-TYPE CALCIUM CHANNEL INHIBITOR | UNIV KINKI (JP) | 2021-03-31 | — | — | EP | claimed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | CACNA1H 1289/4885CACNA1G 1550/4885ESR1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.